SCHEMBL23675403

SCHEMBL23675403

Nc1ccc(CNC(=O)c2cc(Cl)ccc2O)c(Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.55
NR1H4 Q96RI1 1/20 0.55
CDK1 P06493 1/20 0.52
P2RX1 P51575 4/20 0.52
TMPRSS4 Q9NRS4 3/20 0.52
ERCC1 P07992 3/20 0.50
ERCC4 Q92889 3/20 0.50
AKR1B1 P15121 1/20 0.49
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.48
NLRP1 Q9C000 1/20 0.48
TSHR P16473 1/20 0.48
TUBB P07437 2/20 0.47
KCNMA1 Q12791 1/20 0.47
CASP1 P29466 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
P2RX4 Q99571 1/20 0.46
P2RX7 Q99572 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23675382 0.90 ERCC1 (0.59) EPHX2CDK1P2RX1TMPRSS4ERCC1
SCHEMBL30100395 0.90 ERCC1 (0.59) EPHX2CDK1P2RX1TMPRSS4ERCC1
SCHEMBL23675437 0.84 P2RX1 (0.56) EPHX2CDK1P2RX1TMPRSS4ERCC1
SCHEMBL23675419 0.80 NPC1 (0.65) P2RX1TMPRSS4LMNAMAPK1TSHR
SCHEMBL29335953 0.78 LMNA (0.71) EPHX2NR1H4LMNAMAPK1NLRP1
SCHEMBL29617476 0.78 KCNMA1 (0.68) P2RX1TMPRSS4LMNAMAPK1TSHR
SCHEMBL11887644 0.78 KCNMA1 (0.68) P2RX1TMPRSS4LMNAMAPK1TSHR
SCHEMBL26096321 0.77 ALDH1A1 (0.48) EPHX2NR1H4CDK1P2RX1TMPRSS4
SCHEMBL23675392 0.76 TAS1R3 (0.62) CDK1P2RX1TMPRSS4ERCC1ERCC4
SCHEMBL23675446 0.76 TUBB (0.72) CDK1P2RX1TMPRSS4ERCC1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
EP-4093401-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING The Board of Regents of the University of Texas System (US) 2022-11-30 EP disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE EPHX2 2573/4885NR1H4 4072/4885CDK1 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.